Pharma stock jumps 18% after board sets record date for share buyback

SYNOPSIS: Nectar Lifescience approved an Rs. 81 crore share buyback at Rs. 27 per share, amounting to 3 crore shares via the tender route, excluding promoters, with 24th December 2025 set as the record date.

During Wednesday’s trading session, shares of a company engaged in the manufacturing of APIs and Formulations surged nearly 18 percent on BSE, after the Board of the company approved a share buyback worth Rs. 81 crores with a record date fixed on 24th December 2025.

At 10:51 a.m., the shares of Nectar Lifescience Limited were trading in the green at Rs. 20.58 on BSE, up by around 15 percent, as against its previous closing price of Rs. 17.92, with a market cap of Rs. 461.5 crores. The stock has delivered negative returns of over 40 percent in one year, and has gained by around 46 percent in the last one month.

What’s the News:

According to the latest disclosures filed with the stock exchanges, the Board of Directors of Nectar Lifescience Limited, at its meeting held on 3rd December 2025, approved a buyback of equity shares amounting to Rs. 81 crore at a price of Rs. 27 per share, payable in cash. The buyback will involve the purchase of 3 crore fully paid-up equity shares of face value Rs. 1 each, representing up to 13.38 percent of the company’s total paid-up equity share capital, based on the eligible shareholders as of the record date.

The buyback size is within the statutory limit, not exceeding 10 percent of the total paid-up equity capital and free reserves of the company on both a standalone and consolidated basis, as per the audited financial statements for the year ended 31st March 2025.

The buyback will be conducted through the “tender offer” route, open to all equity shareholders excluding the promoters and members of the promoter group, with shares being accepted on a proportionate basis.

It was clarified that the buyback size excludes expenses and transaction-related costs such as brokerage, filing fees, advisory charges, intermediary fees, publication expenses for public announcements, printing and dispatch costs, and applicable taxes, including STT, GST, stamp duty, and other incidental and related charges. The company has fixed 24th December 2025 as the record date to determine the list of shareholders eligible to participate in the buyback.

Financials & More:

Nectar Lifescience recorded a marginal contraction in revenue from operations, declining over 12 percent YoY from Rs. 5.7 crore in Q2 FY25 to Rs. 5 crore in Q2 FY26.

The company also reported a significant deterioration in profitability, slipping to a net loss of Rs. 176 crore in Q2 FY26, compared with a net profit of Rs. 5.8 crore in the corresponding period last year.

Nectar Lifesciences Limited is an integrated pharmaceutical organisation with sustainable production systems to manufacture APIs and formulations. The company is also in the menthol business, serving both the domestic and international markets.

Written by Shivani Singh

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock jumps 18% after board sets record date for share buyback appeared first on Trade Brains.